Additionally, TAGLN2 promotes PAH by modulating cysteinylglycine disulfide (mediated by 3.15%) and eicosenedioate (mediated by 5.21%), suggesting that metabolic imbalance is a significant contributor to PAH pathogenesis. The gene discussed is TAGLN2; the disease is pulmonary arterial hypertension.